Inhibrx Biosciences (INBX) said late Tuesday that Brendan Eckelman, its co-founder and chief scientific officer, will leave the company to form a private biotechnology firm that signed an exclusive license agreement with Inhibrx.
The deal is for the rights to certain technologies no longer being pursued by Inhibrx. The pact includes an upfront payment upon completion of the initial funding of Eckelman's new company and other future development milestones.
Carlos Bais, Inhibrx's executive vice president of translational sciences, will be appointed chief scientific officer and David Matly will become president, in addition to his existing role as chief commercial and business development officer.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。